BIOVAXYS ANNOUNCES CONVERSION OF DEBENTURES

Written by Emily J. Thompson, Senior Investment Analyst

Source: PRnewswire

Updated: Oct 22 2025

0mins

Source: PRnewswire

Debenture Conversion Announcement: BioVaxys Technology Corp. has announced the conversion of $160,670 of outstanding unsecured convertible debentures into common shares, resulting in the issuance of 954,179 shares at a conversion price of $0.17 per share.
Company Overview: BioVaxys is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for cancer and other diseases, utilizing its DPX™ immune-educating technology platform.
Clinical Development: The company is advancing its lead product, maveropepimut-S (MVP-S), in Phase IIB clinical trials for advanced cancers, demonstrating a targeted immune response and clinical benefits.
Regulatory Compliance: The securities issued in connection with the debentures are subject to regulatory approvals, and the company emphasizes that this announcement does not constitute an offer to sell securities in the United States.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.